NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics Inc (NASDAQ:AKCA) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.34) EPS for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.21. The company had revenue of $20.62 million for the quarter, compared to analysts' expectations of $22.54 million. Akcea Therapeutics had a negative return on equity of 33.00% and a negative net margin of 50.71%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. View Akcea Therapeutics' Earnings History.

Akcea Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Akcea Therapeutics.

4 Wall Street analysts have issued 1-year price objectives for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $45.00. On average, they expect Akcea Therapeutics' stock price to reach $36.00 in the next year. This suggests a possible upside of 86.5% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.

Press coverage about AKCA stock has been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Akcea Therapeutics.

Some companies that are related to Akcea Therapeutics include ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP), Allakos (ALLK), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Nektar Therapeutics (NKTR) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Achaogen (AKAO), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Apollo Global Management (APO) and Ciena (CIEN).

(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (0.66%), Alps Advisors Inc. (0.20%), Russell Investments Group Ltd. (0.07%), Squarepoint Ops LLC (0.02%) and Barclays PLC (0.02%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Institutional Ownership Trends for Akcea Therapeutics.

AKCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and Alps Advisors Inc.. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg, Paula Soteropoulos and Sarah Boyce. View Insider Buying and Selling for Akcea Therapeutics.

AKCA stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Barclays PLC. View Insider Buying and Selling for Akcea Therapeutics.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $19.30.

Akcea Therapeutics has a market capitalization of $1.81 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.View Additional Information About Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]